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Extraintestinal Manifestations of Inﬂammatory Bowel Disease
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Abstract: Extraintestinal manifestations (EIM) in inﬂammatory bowel disease (IBD) are frequent and may occur before or after IBD diagnosis. EIM may
impact the quality of life for patients with IBD signiﬁcantly requiring speciﬁc treatment depending on the affected organ(s). They most frequently affect joints,
skin, or eyes, but can also less frequently involve other organs such as liver, lungs, or pancreas. Certain EIM, such as peripheral arthritis, oral aphthous ulcers,
episcleritis, or erythema nodosum, are frequently associated with active intestinal inﬂammation and usually improve by treatment of the intestinal activity. Other
EIM, such as uveitis or ankylosing spondylitis, usually occur independent of intestinal inﬂammatory activity. For other not so rare EIM, such as pyoderma
gangrenosum and primary sclerosing cholangitis, the association with the activity of the underlying IBD is unclear. Successful therapy of EIM is essential for
improving quality of life of patients with IBD. Besides other options, tumor necrosis factor antibody therapy is an important therapy for EIM in patients with IBD.
(Inﬂamm Bowel Dis 2015;21:1982–1992)
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I nﬂammatory bowel disease (IBD), which includes Crohn’s disease(CD) and ulcerative colitis (UC), should be regarded as a systemic
disorder not limited to the gastrointestinal tract because many patients
will develop extraintestinal symptoms. Extraintestinal symptoms may
involve virtually any organ system with a potentially detrimental
impact on the patient’s functional status and quality of life.
Extraintestinal symptoms can be divided in 2 groups: extra-
intestinal manifestations (EIM) and extraintestinal complications.
EIM most frequently affect joints (peripheral and axial arthropathies),
the skin (erythema nodosum, pyoderma gangrenosum, Sweet’s syn-
drome, aphthous stomatitis), the hepatobiliary tract (primary scleros-
ing cholangitis [PSC]), and the eye (episcleritis, uveitis) (Fig. 1). Less
frequently, EIM also affect the lungs, the heart, the pancreas, or the
vascular system. Extraintestinal complications are mainly caused by
the disease itself and include conditions such as malabsorption with
consequent micronutrient deﬁciencies, osteoporosis, peripheral neu-
ropathies, kidney stones, gallstones, and IBD drug-related side effects.
This article focuses on the clinical features of EIM. Certain
EIM such as pauciarticular arthritis, oral aphthous ulcers, erythema
nodosum, or episcleritis usually occur with increased intestinal
disease activity.1,2 Other EIM such as ankylosing spondylitis and
uveitis usually follow an independent course from IBD disease activ-
ity.1,2 And ﬁnally, some EIM such as PSC and pyoderma gangreno-
sum may or may not be related to IBD disease activity (Table 1).2–4
EIM in IBD are reported with frequencies ranging from 6% to
47%.5–13 Multiple EIM may occur concomitantly, and the presence
of 1 EIM confers a higher likelihood to develop other EIM.14
Recently, we reported based on data from the Swiss IBD Cohort
study that up to 1 quarter of EIM-affected patients with IBD tend to
suffer from a combination of several EIMs (up to 5).14 Furthermore,
our group recently published data regarding the chronological order
of EIM appearance relative to IBD diagnosis.15 A summary of the
chronologic appearance of EIMs relative to IBD diagnosis is pre-
sented in Figure 2. In 25.8% of cases, a ﬁrst EIM occurred before
IBD was diagnosed (median time 5 mo before IBD diagnosis; range,
0–25 mo). In 74.2% of cases, the ﬁrst EIM manifested after IBD
diagnosis was made (median, 92 mo; range, 29–183 mo) (Fig. 2).
We found that up to 4 different EIM occurred before IBD was
diagnosed, and that at 30 years after IBD diagnosis, 50% of patients
had suffered from at least 1 EIM. Perianal CD, colonic involvement,
and cigarette smoking increased the likelihood to suffer from EIMs.16
PATHOGENESIS OF EIM
The pathogenesis of EIM in IBD is not well understood. It
is believed that the diseased gastrointestinal mucosa may trigger
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immune responses at the extraintestinal site due to shared
epitopes, e.g., of intestinal bacteria and the synovia.17–21 This
would mean that bacteria that are translocated across the leaky
intestinal barrier trigger an adaptive immune response that ﬁnally
is unable to discriminate between bacterial epitopes and epitopes
of joints or the skin. Triggers of the autoimmune responses in
certain organs seem to be inﬂuenced by genetic factors. Concor-
dance in EIM was present in 70% of parent–child pairs and 84%
in sibling pairs.10,22 Associations of EIM in IBD with major his-
tocompatibility complex loci have been demonstrated. EIM in
patients with CD are more frequently observed in patients with
HLA-A2, HLA-DR1, and HLA-DQw5, whereas EIM in patients
with UC are more likely to appear when the HLA-DR103 geno-
type is present.23 Particular HLA complexes have also been linked
to speciﬁc EIM. HLA-B8/DR3 is associated with an increased
risk of PSC in UC, whereas HLA-DRB1*0103, HLA-B*27,
and HLA-B*58 are associated with EIM of joints, the skin, and
eyes, respectively, in patients with IBD.4,24,25 HLA-B*27 itself
does not seem to be associated with IBD5 but HLA-B*27 shows
a strong association with the development of ankylosing spondy-
litis, as 50% to 90% of patients with IBD are positive for this
marker.26 As HLA-B*27 per se shows an association with anky-
losing spondilitis or rheumatoid arthritis it remains unclear
whether there is a speciﬁc role for EIM in IBD.
MUSCULOSCELETAL EIM
Musculoskeletal EIM including joint complaints represent
the most common EIMs in IBD. Joint symptoms affecting
peripheral large and small joints or the axial joints occur in up
to 40% of patients with IBD.14,27,28
Peripheral Arthralgia/Arthritis
Peripheral arthralgia/arthritis in patients with IBD, in
contrast to other speciﬁc forms of arthritis such as rheumatoid
arthritis or psoriatic arthritis, shows little or no joint destruction.
Classically, it presents as a seronegative arthralgia/arthritis,1
which affects 5% to 10% of patients with UC and 10% to 20%
FIGURE 1. A, Oral aphthous ulcers, (B) Sweet’s syndrome, (C) erythema nodosum, (D) pyoderma gangrenosum, (E) peristomal pyoderma gan-
grenosum, (F) episcleritis, (G) uveitis with hypopyon and dilated iris vessels, (H) conventional x-ray of the lateral spine demonstrating syn-
desmophytes (bamboo spine), (I) plane radiograph of the ileosacral joints with bilateral sacroiliitis, (J) plane radiography of the sacrum with
bilateral ankylosis, (K) coronal magnetic resonance image of the sacroiliac joints with active inﬂammation mainly on the left side and chronic
inﬂammatory changes on both sides.
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of patients with CD.29 A higher risk for peripheral arthralgia/
arthritis is seen in patients with IBD with colonic involvement
and in patients suffering from perianal disease, erythema nodo-
sum, stomatitis, uveitis, and pyoderma gangrenosum.1,20
Peripheral arthralgia/arthritis has been classiﬁed into 2
entities (Table 2): type I (pauciarticular) arthralgie/arthritis usually
affects less than 5 large joints, such as ankles, knees, hips, wrists,
elbows, and shoulders and is often acute, asymmetrical, and
migratory. The knee is commonly involved. Approximately,
20% to 40% of all patients have more than 1 episode of arthral-
gia/arthritis. Pauciarticular arthralgia/arthritis is usually related to
IBD activity and self-limiting with a maximum duration of up to
10 weeks.29 Consequently, medical or surgical treatment of the
underlying intestinal inﬂammation (i.e., colitis) is usually associ-
ated with improvement of type I arthritis. Type II (polyarticular)
arthralgia/arthritis frequently is a symmetrical arthritis involving 5
or more small joints. It is not related with intestinal disease activ-
ity and may precede IBD diagnosis. Type II arthropathy can
persist for years (median of 3 yr).29 The metacarpophalangeal
joint is most commonly involved. Type II arthritis is associated
with an increased risk of uveitis but not erythema nodosum.29
The diagnosis/classiﬁcation of type 1 and type 2 arthro-
pathies is purely clinical, as imaging is most often normal with no
evidence of signiﬁcant inﬂammation or joint destruction.31 Both
types are seronegative (i.e., rheumatoid factor-negative), but may
represent immunogenetically distinct entities. Type 1 peripheral
arthropathy is associated with HLA-B27, HLA-B35, and HLA-
DR103, whereas type 2 is associated with HLA-B44.25
As type II peripheral arthropathy usually occurs indepen-
dently from intestinal activity and anti-inﬂammatory treatment
may not be successful, physiotherapy and treatment of associated
pain is the main treatment option in those cases.
Table 3 summarizes treatment options of EIM in IBD.
Other treatment modalities include rest, and intra-articular ste-
roid injections. Use of sulphasalazine has been reported to
improve peripheral arthropathies.45 Therapy with nonsteroidal
anti-inﬂammatory drugs (NSAIDs) in the management of
IBD-associated peripheral arthropathies requires caution
FIGURE 2. Chronology of EIM in patients with IBD. In one quarter of
patients with IBD, up to 4 EIM appeared before the time of IBD
diagnosis. The median time before IBD diagnosis is 5 mo (range, 0–25
mo). In 75% of cases, the ﬁrst EIM manifested after IBD diagnosis
(median, 92 mo; range, 29–183 mo). Thirty years after diagnosis up to
50% of patients with IBD have suffered from at least 1 EIM.15
TABLE 1. Relationship Between EIM Activity and
Intestinal Activity
EIM
Parallel
Course
of IBD
Separate
Course of
IBD
May or May
Not Parallel
Disease Activity
Axial arthropathy ✓
Peripheral arthropathy ✓ ✓
(Type I) (Type II)
Erythema nodosum ✓
Pyoderma gangrenosum ✓
Sweet’s syndrome ✓
Oral aphthous ulcers ✓
Episcleritis ✓
Uveitis ✓
PSC ✓
Adapted from Trikudanathan et al.2
TABLE 2. Classiﬁcation of Peripheral Arthropathy
Associated with IBD
Type 1 (Pauciarticular) Type 2 (Polyarticular)
Prevalence in UC, 35% Prevalence in UC, 24%
Prevalence in CD, 29% Prevalence in CD, 20%
Less than 5 joints Five or more joints
Mainly large joints Mainly small joints
Knee . ankle . wrist .
elbow . MCP .
hip . shoulder
MCP . knees . PIP . wrist .
ankle . elbow . shoulder
Asymmetric involvement It can be symmetric or asymmetric,
may be erosive
Parallels intestinal disease activity Clinical course independent of IBD
activity
Self-limited episodes that last
,10 wk
Persistent inﬂammation for months
or even years
High frequency of other EIM
(erythema nodosum and uveitis)
Associated only with uveitis
Associated with HLA-B27, B35,
and DR103
Associated with HLA-B44
PIP, proximal interphalangeal joint; MCP, metacarpophalangeal joint.
Combined use of the Assessment of SpondyloArthritis International Society (ASAS)
criteria for axial spondyloarthritis (SpA) and the ASAS criteria for peripheral SpA in the
entire SpA population. In patients with predominantly axial involvement (back pain) with
or without peripheral manifestations, the ASAS criteria for axial SpA6 are applied. In
patients with peripheral manifestations only, the ASAS criteria for peripheral SpA are
applied. In the entire ASAS population of 975 patients’ sensitivity and speciﬁcity of the
combined use of the 2 sets of criteria were 79.5% and 83.3%, respectively.
Adapted from Su et al,10 Orchard et al,29 and Rodriguez-Reyna et al.30
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because of the reported association of exacerbation of IBD with
NSAID use.46–50
In a study by Takeuchi et al, up to 25% of patients in
remission experienced a disease ﬂare when provided certain
NSAIDs. It seems that COX-2 inhibitors may show a better safety
proﬁle and might be used with caution in patients with IBD
suffering from peripheral arthropathies.49,51–54
Whether a discrimination of type I and type II arthropathy is
clinically useful and meaningful has never been studied in detail. In
most large IBD centers, this discrimination is not used. In fact,
affection of small joints may disappear as well with the treatment of
the underlying disease, whereas inﬂammation of the large joints may
also occur as side effect of anti-TNF therapy. A careful documen-
tation of joint affections, which is standard in rheumatology, certainly
would be helpful and could improve the outcome of patients with
IBD. This should be requested as a standard in IBD centers.
Axial Arthropathies
Axial arthropathies are less frequent than peripheral
arthralgia/arthritis in patients with IBD, occurring in 3% to 5%
of patients although frequencies of up to 25% have been
reported.9–13,55 Males are more frequently affected than females.
In contrast to peripheral arthralgia/arthritis (at least in contrast to
type I arthropathy), axial arthropathies are usually independent of
the intestinal IBD activity. Axial arthropathies can be categorized
into ankylosing spondylitis and sacroiliitis. Ankylosing spondyli-
tis in patients with IBD occurs in 5% to 10% of patients and is
mainly HLA-B27–positive.10,56,57 Patients with ankylosing spon-
dylitis often experience severe onset of back pain at young age,
usually associated with morning stiffness or pain exacerbation by
periods of rest. Physical examination reveals limited spinal ﬂexion
(Schober’s test) and reduced chest expansion. Radiographs in
early stages may be normal or show only minimal sclerosis.
The disease course is usually progressive, resulting in permanent
skeletal damage. Patients with IBD with advanced ankylosing
spondylitis may show squaring of vertebral bodies, marginal syn-
desmophytes, bone proliferation, and ankylosis, features classi-
cally described as bamboo spine.
Sacroiliitis is observed radiographically in up to 25% of
patients.6,48 Most patients with sacroiliitis are HLA-B27–negative
TABLE 3. Treatment Options of EIM in IBD
EIM Organ Speciﬁc EIM First-line Therapy Second-line Therapy References
Joints Peripheral arthritis Intraarticular/oral steroids,
sulfasalazine, immunomodulators,
COX-2 inhibitors; treatment
of IBD ﬂare (type 1)
IFX, adalimumab Generini et al32
Type 1 (large joints) Herfarth et al33
Type 2 (small joints) Atzeni et al34
Axial arthropathies Physiotherapy, COX-2 inhibitors,
MTX, sulfasalazine
IFX, adalimumab Sarzi-Puttini et al35
Ankylosing spondylitis Kaufmann et al36
Sacroileitis Generini et al32
Skin Pyoderma gangrenosum Oral steroids, cyclosporine,
immunosupressives
IFX, adalimumab Brooklyn et al37
Kaufmann et al36
Regueiro et al38
Erythema nodosum Treatment of IBD ﬂare IFX, adalimumab In Bechet’s disease
Tanida et al39
Sweet’s syndrome Topical/systemic steroids IFX Vanbiervliet et al40
Aphthous ulcers Treatment of IBD ﬂare, topical steroids, oral
steroids, topical lidocaine
IFX Kaufman et al35
Liver PSC Endoscopic retrograde cholangiography
for dilatation of dominant strictures,
UDCA up to 15 m/kg, controversial
for high dose
Transplantation Singh et al41
Eyes Uveitis Topical/systemic steroids, cyclosporine IFX Fries et al42
Hernandez Garfella43
In Bechet’s disease
Episcleritis Treatment of IBD ﬂare, topical steroids Lakatos44
Adapted from Lakatos et al.44
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and do not progress to ankylosing spondylitis. Patients with the
radiographic ﬁnding of bilateral sacroiliitis are more likely to
progress to ankylosing spondylitis.58
Treatment options of peripheral arthralgia/arthritis and axial
arthropathies in IBD are summarized in Table 3. Therapeutic agents
for axial arthropathies that have been reported include sulfasalazine,
mesalamine, methotrexate (MTX), azathioprine, thalidomide, and
anti-tumor necrosis factor therapy.32,59–61 TNF-antibodies such as
inﬂiximab and adalimumab have shown an improvement of axial
arthropathies in several studies in patients with IBD and should be
used especially in refractory cases.31,32,44,61–64
Axial arthropathies can impact work ability and cause an
additional burden for patients with IBD. The diagnosis of axial
arthropathies is followed by an access to medications that
frequently are not approved for the treatment of patients with
IBD. The treatment of axial arthropathies frequently is initiated by
rheumatologists. However, it needs to be highlighted that this has
to happen in close collaboration with the gastroenterologist.
Enbrel, which has been found not to be effective in IBD, is not
a good treatment option for ankylosing spondylitis in patients
with IBD.
EIM OF THE SKIN
The diagnosis of cutaneous EIM in IBD is based on the
clinical picture and on their characteristic features and the
exclusion of other speciﬁc skin disorders. Cutaneous disorders
associated with IBD occur in up to 15% of patients.11,14
Erythema Nodosum
Erythema nodosum occurs in up to 15% of patients with
CD and 10% of patients with UC.11 Other publications report
a considerably lower frequency.4,14,65 Preponderance in female
patients has been suggested.65,66 Furthermore, erythema nodosum
is frequently associated with eye and joint involvement, isolated
colonic involvement, and pyoderma gangrenosum.65
Erythema nodosum is usually easily recognized as raised,
tender, red, or violet inﬂammatory subcutaneous nodules of 1 to 5
cm in diameter, typically on the anterior extensor surface of the
lower extremities but rarely on the face and trunk.11 It shows
preponderance in females and patients with CD.14,66 Unpublished
data from the Swiss IBD Cohort Study indicate that location of
erythema nodosum does not differ signiﬁcantly between patients
with CD and UC. Figure 3 illustrates the distribution of erythema
nodosum lesions in male and female patients with IBD. The diag-
nosis is established based on clinical judgment, and skin biopsies
are rarely required. Erythema nodosum usually heals without
scars. Its onset coincides with acute ﬂares of IBD and is fre-
quently self-limiting or improves with treatment of the underlying
IBD.13 Mild cases may be treated with leg elevation, use of an-
algesics, potassium iodine, systemic corticosteroids, and compres-
sion stockings.67
In severe or refractory cases, alternative causes of erythema
nodosum should be investigated such as infections with
Streptococcus, Yersinia pseudotuberculosis, Yersinia enterocoli-
tica, syphilis, sarcoidosis, Behcet’s disease, and use of oral contra-
ceptives or other medication. After exclusion of other causes,
severe cases may require systemic corticosteroids or immunosup-
pressive therapy or TNF antibodies. Only a few case reports high-
light the beneﬁt of inﬂiximab and adalimumab for erythema
nodosum.68–71 Please refer to Table 3 for an overview of treatment
options of EIM in IBD.
Pyoderma Gangrenosum
Pyoderma gangrenosum is a much rarer, more severe,
debilitating EIM, more common in UC than in CD. It affects
women more frequently than men72,73 and is associated with black
African origin, familial history of UC, and pancolitis as the initial
location of IBD, permanent stoma, eye involvement, and ery-
thema nodosum.65 The prevalence of pyoderma gangrenosum in
IBD is 0.4% to 2%.4,6,14,66,74 Vice versa, up to 50% of patients
with pyoderma gangrenosum have underlying IBD.1 The lesions
are usually preceded by a trauma (even many years earlier)
through a phenomenon known as pathergy. This trauma can even
be minimal such as venous puncture or biopsy. Figure 4 shows the
distribution of location of pyoderma gangrenosum lesions in male
and female patients suffering from IBD in the SIBDCS.
Patients with severe disease and colonic involvement are
most likely to develop this complication.75 The disease course is
unpredictable. Pyoderma gangrenosum usually begins as an ery-
thematous pustule or nodule that spreads rapidly to the adjacent
skin and develops into a burrowing ulcer with irregular violaceous
edges.76 The deep ulcerations often contain purulent material,
which is sterile on culture. These ulcers can be solitary or multi-
ple, unilateral, or bilateral, and can range in size from several
centimeters to an entire limb. The most common sites includes
extensor surfaces of the legs (shins) and adjacent to a postsurgical
stoma but can occur anywhere on the body, including the genita-
lia.75 Peristomal pyoderma gangrenosum is seen occasionally as
a complication in patients with IBD. One study followed 20 con-
secutive peristomal pyoderma gangrenosum patients and reported
only limited success with local enterostomal care, debridement,
and/or stomal revision but responded to a variety of medical
therapies.77 All these peristomal ulcers healed completely within
a median of 11.4 months (range, 1–42 mo). Another smaller study
reported on 7 patients with peristomal pyoderma gangrenosum,78
4 of which occurred in patients with IBD. Intravenous cyclospor-
ine and inﬂiximab were tried in some of those patients with
success.
Cases of pyoderma gangrenosum evolving from preceding
erythema nodosum also have been reported.79 The diagnosis is
made clinically, although wound swabs and a skin biopsy may be
needed to exclude other conditions. There are no pathognomonic
histological features, generally revealing only diffuse neutrophil
inﬁltration and dermolysis. Pyoderma gangrenosum has typically
no association to the clinical activity of the underlying intestinal
disease; however, pyoderma gangrenosum may resolve with treat-
ment of the IBD. Up to 36% to 50% of patients with pyoderma
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gangrenosum have IBD.80 Pyoderma gangrenosum may resolve
with treatment of the underlying IBD (Table 3). Mild cases usu-
ally respond to local and topical therapy, including intralesional
corticosteroid injections, moist treatment with hydroactive dress-
ings, and topical sodium cromoglycate.76,81,82 Effective systemic
agents include oral sulfasalazine, dapsone, corticosteroids, and
immunomodulators such as azathioprine, cyclophosphamide,
cyclosporine, methotrexate, tacrolimus, and mycophenolate
mofetil.67,76,81,83,84
Rapid healing of these lesions should be the therapeutic aim
because pyoderma gangrenosum can be a debilitating skin
disorder. However, response to therapy varies, and many patients
with pyoderma gangrenosum have a disease course that is
refractory to these agents. Adalimumab and inﬂiximab are
efﬁcient treatment options in severe pyoderma gangrenosum
cases and have been reported in several case reports and case
series.35–37,64,77,78,85–105 For an overview on TNF-antibody thera-
pies in EIM, please see Vavricka et al.64
PG is initially sometimes treated by surgical debridement. A
surgical intervention typically worsens PG. If there is any doubt
about the nature of an ulcer in patients with IBD, surgical
debridement should be avoided until a PG is excluded. It has been
discussed whether a maintenance treatment also is necessary for PG.
Sweet’s Syndrome
Sweet’s syndrome, or acute febrile neutrophilic dermatosis,
is a rare dermatologic manifestation associated with CD and
UC.106,107 Besides IBD, Sweet’s syndrome may also be associated
with other systemic diseases such as malignancy. The cutaneous
lesion of Sweet’s syndrome manifests as tender or papulosqua-
mous exanthema or nodules involving the arm, legs, trunk, hands,
or face. Other characteristic features of Sweet’s syndrome are
leukocytosis and histologic ﬁndings of a neutrophilic inﬁltrate.
Associated systemic manifestations include arthritis, fever, and
ocular symptoms, such as conjunctivitis. Its association with
IBD usually parallels the gastrointestinal disease activity but
may precede the diagnosis of IBD.108 The use of azathioprine
has been implicated in the development of Sweet’s syndrome in
a patient with IBD.109,110 Table 3 reports on the treatment options
of EIMs in IBD. Most cases of Sweet’s syndrome respond to
topical or systemic corticosteroid therapy111 and heal without
scarring. Metronidazole has been reported to be effective in 1 case
report.108
Oral Lesions
The oral cavity is frequently affected in patients with IBD,
especially the ones suffering from CD. Periodontitis and other
lesions such as aphthous stomatitis and, in more severe cases,
pyostomatitis vegetans are found in up to 10% of patients with
IBD.10,14,112 Both diseases follow the course of the underlying
IBD. Aphthous lesions are typically located on the labial and
buccal mucosa but may also affect the tongue and oropharynx.
Pyostomatitis vegetans manifests as multiple pustular sometimes
hemorrhagic eruptions anywhere on the oral mucosa with
FIGURE 3. Unpublished data from the Swiss IBD cohort study.15 Location of erythema nodosum in male and female patients suffering from IBD.
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a cobblestone pattern. Therapy includes antiseptic mouthwashes
and topical steroids (Table 3).67,105
OCULAR MANIFESTATIONS
Beside joints and skin, the eye is the third major tissue type
predisposed to immune-mediated EIMs. Nearly, 2% to 5% of
patients with IBD experience ocular manifestations,10,13,113 particu-
larly associated with concomitant musculoskeletal manifestations.4
Ocular manifestations are reported more frequently in patients with
CD (3.5%–6.3%) than patients with UC (1.6%–4.6%) and include
episcleritis and uveitis.9,11,13,14,55 Patients older than 40 years have
more likely iritis/uveitis than those younger than 40 years.6
Episcleritis is deﬁned as painless hyperemia of the conjunc-
tiva and sclera without changes of virus and often parallels the
activity of the underlying IBD. Besides episcleritis, anterior uveitis
is the most common ocular manifestations of IBD. The different
types of uveitis are divided as follows: (1) anterior uveitis has its
primary site of inﬂammation in the anterior chamber, (2) interme-
diate uveitis with its primary site of inﬂammation being the
vitreous, (3) posterior uveitis with its primary site of inﬂammation
being the retina and the choroid, and (4) panuveitis with its primary
site of inﬂammation including anterior chamber, vitreous, retina,
and choroid. Uveitis occurs independently of disease activity and is
deﬁned as inﬂammation of the middle chamber of the eye. Uveitis
occurs acutely or subacutely and is usually very painful. Anterior
uveitis is also referred to as iritis, which typically presents as pain,
photophobia, and red eye and can be associated with blurry vision
or ﬂoaters. Diagnosis is conﬁrmed by slit-lamp examination. An
increasing number of case reports and pilot studies exist on the
therapy of uveitis and episcleritis; however, only few reports focus
on patients with IBD.42,114–124
Episcleritis and Scleritis
Episcleritis is more common in CD than in UC.1 It is char-
acterized by acute hyperemia, irritation, burning, and tenderness.
Episcleritis usually does not need speciﬁc treatment other than
those for the underlying disease. Scleritis affects the deeper layers
of the eye and can cause visual impairment if not diagnosed early.
Patients often complain of severe pain associated with tenderness
to palpation.125 Recurrent scleritis can lead to scleromalacia, ret-
inal detachment, or optic nerve swelling. If therefore mandates
aggressive treatment. Disease-speciﬁc treatment and topical ste-
roid therapy usually provide prompt relief of symptoms (Table 3).
In case of impairment of vision, the presence of scleritis
must be suspected, and prompt referral to an ophthalmologist is
mandatory to avoid vision loss.
Uveitis
Uveitis is less common than episcleritis and occurs in 0.5%
to 3% of patients with IBD.4 When associated with UC, it is
FIGURE 4. Unpublished data from the Swiss IBD cohort study.15 Location of pyoderma gangrenosum in male and female patients suffering from IBD.
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frequently bilateral, insidious in onset, and long-lasting.4 It
presents as ocular pain, blurred vision, photophobia, and head-
aches. In contrast to episcleritis, the temporal correlation of uveitis
with IBD is less predictable, and its occurrence may precede the
diagnosis of IBD. On slit-lamp examination, uveitis presents as
a perilimbic edema and inﬂammatory ﬂare in the anterior cham-
ber.125 Prompt diagnosis and treatment with topical and systemic
corticosteroids is necessary to prevent progression to blindness.
Steroid refractory cases are treated with cyclosporine A (Table 3).
Successful use of inﬂiximab for IBD-associated uveitis was dem-
onstrated in a patient with CD with uveitis and sacroileitis.42
HEPATOBILIARY EIM
Up to 50% of patients with IBD are affected by hepato-
biliary manifestations during the course of their disease.5 PSC,
small-duct PSC, fatty liver disease, granulomatous hepatitis, auto-
immune liver and pancreas disease, cholestasis, gallstone forma-
tion, and liver injury are hepatobiliary manifestations of IBD.126
PSC Is the Most Frequent Biliary
Manifestation of IBD
It is more common in patients with UC than in CD.
Approximately, 2.4% to 7.5% of patients with UC are diagnosed
with PSC.127,128 Conversely, 75% of patients with PSC suffer
from IBD, typically UC.129,130 PSC manifests with inﬂammation
and ﬁbrosis of the biliary system that presents clinically with
a chronic cholestatic disease. A cholestatic biochemical proﬁle
is seen, and characteristic features are frequently found on chol-
angiography. These include multifocal bile duct strictures and
segmental dilatation. PSC can precede the diagnosis of IBD; how-
ever, some patients are even diagnosed with PSC several years
after proctocolectomy due to UC.3
Patients with PSC should undergo colonoscopy to evaluate
concomitant IBD. Extensive involvement of the colon with rectal
sparing, backwash ileitis in UC, and predominance in male
patients are typical features of PSC.3,130 Patients with PSC can
develop bouts of acute cholangitis and ultimately progress to
cirrhosis, portal hypertension, and acute decompensation.131 Inter-
estingly, the diagnosis of PSC seems to inﬂuence the course of
IBD, as patients with both PSC and UC are suggested to have
a milder course of their colitis with less histological inﬂammation
of the colon than patients without PSC.132 Nevertheless, the pres-
ence of PSC is an independent risk factor for the development of
colorectal dysplasia and/or cancer in patients with IBD, leading to
the recommendation for annual surveillance colonoscopies in
affected patients from the time of ﬁrst diagnosis of IBD.133–135
The natural course of PSC is independent of IBD, and the bile
duct damage is irreversible and nonresponsive to medication. Ur-
sodeoxycholic acid is used widely in patients with PSC; however,
only limited effect has been shown. Ursodeoxycholic acid is re-
ported to improve liver enzymes; however, the disease course of
PSC is not changed.136 Some patients with dominant strictures on
endoscopic retrograde cholangiography might improve with
dilatation. The majority of patients with PSC ultimately require
liver transplantation.
CONCLUSIONS
IBD is a systemic disease, and EIM are the proof that IBD
is not only limited to the gut. Those EIM may affect multiple
organs beyond the intestine. Sometimes, these EIM can even be
more debilitating than the intestinal disease. Careful screening for
EIMs in these patients and early appropriate diagnosis are
imperative to prevent morbidity. In EIM responding to the
underlying IBD, sufﬁcient IBD therapy and careful monitoring
of the EIM is often enough to improve symptoms of the EIM. In
EIM not after the activity of the underlying IBD, a multidisciplin-
ary approach is often needed. Clinicians who care for patients
with IBD must recognize those various systemic manifestations,
as failure to diagnose and treat them early may result in major
morbidity.
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